The Efficacy of Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants

Rotavirus Infection of Children Clinical Trial

— Rota5DCHILE  

Official title:

The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06200844
• Other study ID #: BBIL/Rotavac 5D-CHILE /2022
• Status: Recruiting
• Phase: Phase 3
• Start date: July 7, 2023
• Est. completion date: February 2025

Study information

• Verified date: January 2024
• Source: Bharat Biotech International Limited
• Contact: Krishna Mohan, PhD
• Phone: 04046454520
• Email: Kmohan[@]bharatbiotech.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blind, phase 3 study to evaluate the Efficacy,Safety, and Immunogenicity of ROTAVAC 5D, a live attenuated rotavirus vaccine in healthy infants aged 6-8 weeks.

A total of 5800 healthy Chilean infants will be recruited in this study and randomized to receive either vaccine or placebo in 1:1 ratio. Among these participants 300 will be categorized to immunogenicity cohort, 150 from each group, and blood samples will be collected to assess the immune response.

Description:

The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants.

This is a randomized, double-blind, phase 3 study to evaluate the Efficacy, Safety, and Immunogenicity of ROTAVAC 5D, a live attenuated rotavirus vaccine in healthy infants aged 6-8 weeks.

A total of 5800 healthy Chilean infants will be recruited in this study and randomized to receive either vaccine or placebo in 1:1 ratio. Among these participants 300 will be categorized to immunogenicity cohort, 150 from each group, and blood samples will be collected to assess the immune response. Inclusion At least one parent(s) or legally acceptable representative's consent for participation and are able to understand study procedures Subjects aged 6 to 8 weeks at recruitment No plans to move in the next 12 months Exclusion Administration of rotavirus vaccine in the past Presence of any illness requiring hospital referral (temporary exclusion) Known case of immunodeficiency disease, known HIV positive Known case of chronic gastroenteritis disease, chronic pulmonary disease, chronic renal disease, congenital heart disease Any other conditions which in the judgment of the investigator warrant exclusion (e.g. no exclusion criteria but seems 'ill', investigators suspects neglect) Diarrhea on the day of enrollment (temporary exclusion) A known sensitivity or allergy to any components of the study vaccines. Major congenital or genetic defect. Has received any immunoglobulin therapy and/or blood products since birth. History of chronic administration (defined as more than 14 days) of immunosuppressants including corticosteroids. Infants on inhaled or topical steroids may be permitted to participate in the study, at the discretion of the principal investigator. Blood samples: In the "Immunogenicity Subset", 3 ml blood specimens will be collected at baseline and 28 (+) 5 days after the third dose of the Test Article/placebo to assess the anti rotavirus IgA antibody titer. Stool Specimens: The study team will attempt to collect a stool specimen for every GE episode, preferably within the first 2 days after episode onset. The stool specimen may be collected up to 7 days after the last day of diarrhea. The stool specimens will be sent to the laboratory. If the episode is a suspected intussusception or vaccine associated gastroenteritis that has occurred within four weeks after each dose of the Test Article/placebo, the specimen will be sent to the laboratory immediately for rotavirus testing and typing. For all ELISA RV positive samples, an aliquot of the stool specimen will be assessed for 20 enteropathogens by multiplex-PCR panel and to identify the genotype of the virus.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5800
• Est. completion date: February 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Weeks to 8 Weeks

Eligibility

Inclusion Criteria:

1. At least one parent(s) or legally acceptable representative's consent for participation and are able to understand study procedures

2. Subjects aged 6 to 8 weeks at recruitment

3. No plans to move in the next 12 months

Exclusion Criteria:

1. Administration of rotavirus vaccine in the past

2. Presence of any illness requiring hospital referral (temporary exclusion)

3. Known case of immunodeficiency disease, known HIV positive

4. Known case of chronic gastroenteritis disease, chronic pulmonary disease, chronic renal disease, congenital heart disease

5. Any other conditions which in the judgment of the investigator warrant exclusion (e.g. no exclusion criteria but seems 'ill', investigators suspects neglect)

6. Diarrhea on the day of enrollment (temporary exclusion)

7. A known sensitivity or allergy to any components of the study vaccines.

8. Major congenital or genetic defect.

9. Has received any immunoglobulin therapy and/or blood products since birth.

10. History of chronic administration (defined as more than 14 days) of immunosuppressants including corticosteroids. Infants on inhaled or topical steroids may be permitted to participate in the study, at the discretion of the principal investigator.

Related Conditions & MeSH terms

• Rotavirus Infection of Children
• Rotavirus Infections

Intervention

Biological:
• ROTAVAC 5D
Rotavirus Vaccine (ROTAVAC 5D), is a monovalent vaccine containing suspension of live attenuated rotavirus 116E prepared in Vero cells, containing NLT 105.0 FFU and administered as a three-dose regimen, 4 weeks apart.

Other:
• Placebo
Placebo is administered as three doses 4 weeks apart

Locations

Country	Name	City	State
Chile	Centro de Investigación vacunas Hospital de Puerto Montt	Puerto Montt
Chile	CESFAM Colina	Santiago
Chile	CESFAM Esmeralda	Santiago
Chile	CESFAM Lo Barnechea	Santiago
Chile	CESFAM Lo Barnechea	Santiago
Chile	CESFAM Santa julia	Santiago
Chile	Hospital de ninos Roberto del Rio	Santiago
Chile	Hospital Exequiel Gónzalez Cortés	Santiago
Chile	CESFAM Jean y Marie Thierry de Valparaíso	Valparaíso
Chile	Hospital Gustavo Fricke	Viña Del Mar

Sponsors (1)

Lead Sponsor	Collaborator
Bharat Biotech International Limited

Country where clinical trial is conducted

Chile, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the efficacy of ROTAVAC5D	Efficacy of ORV 116E in comparison to a placebo against moderate-severe rotavirus gastroenteritis defined as: episode of diarrhea (the passage of three or more loose or watery stools within a 24-hour period), with or without vomiting, that requires overnight hospitalization or rehydration therapy equivalent to World Health Organization (WHO) plan B (oral rehydration therapy) or plan C (intravenous rehydration therapy) in a medical facility such as a hospital, clinic, or supervised rural health care center	14 days following the 3rd dose till the age of 1 year (12 months) + up to 14 days].
Secondary	Efficacy of Severe rotavirus gastroenteritis (>11 on the 20 point Vesikari scoring scale) caused by non vaccine rotavirus occurring at least 14 days following the third dose	Severe rotavirus gastroenteritis (>11 on the 20 point Vesikari scoring scale) caused by non vaccine rotavirus occurring at least 14 days following the third dose	Till the age of 12 months + up to 14 days
Secondary	To evaluate the efficacy of a ROTAVAC 5D against any severity of rotavirusgastroenteritis	Any severity of gastroenteritis caused by non vaccine rotavirus from 14 days following the 3rd dose	Till the age of 1 year (12 months) + up to 14 days
Secondary	To evaluate the efficacy of ROTAVAC 5D for rotavirus only gastroenteritis (absence of co-pathogens)	All primary and secondary endpoints indicated above for episodes that result positive only for rotavirus, and no other co-pathogen.	Throughout study period i.e.,30 months
Secondary	To evaluate the efficacy of a ROTAVAC 5D against any severity of gastroenteritis irrespective of etiology	Any severity of gastroenteritis irrespective of etiology from 14 days following the 3rd dose	till the age of 1 year (12 months) + up to 14 days
Secondary	To evaluate the efficacy of ROTAVAC 5D against severe (>11 on the 20 point Vesikari scoring scale) gastroenteritis irrespective of etiology	Severe (>11 on the 20 point Vesikari scoring scale) gastroenteritis irrespective of etiology f	From 14 days following the 3rd dose till the age of 1 year (12months) + up to 14 days
Secondary	To evaluate the intent to treat efficacy of ROTAVAC 5D against severe rotavirus gastroenteritis	Severe rotavirus gastroenteritis (=11 on the 20 point Vesikari scoring scale) caused by non vaccine rotavirus in the intent-to-treat population	till the age of 1 year (12 months) + up to 14 days
Secondary	Safety of the subjects during study period To assess the safety of ROTAVAC 5D for immediate and seven day adverse events, after all the 3 doses	During this period, will be solicited adverse events till 30 minutes after each vaccination (immediate solicited adverse events) and adverse events occurring within 7 days after each vaccination.	From the day of vaccine administration to 7 days for all the three doses.
Secondary	To assess the safety of ROTAVAC 5D for adverse events in the 4-week period following administration of each of the three doses of the vaccine/placebo	Unsolicited adverse events assessed from day 0 to 28 following each dose in comparison to a placebo will be assessed in a subset of subjects	day 0 to 28 following each dose
Secondary	To assess the safety of ROTAVAC 5D for SAEs,especially intussusception events occurring during the study period in all subjects	SAEs with a special focus on Intussusception events in comparison to a placebo will be assessed in all subjects throughout the study period.	from day of 1st dose till the age of 1 year (12 months) + up to 14 days
Secondary	Secondary Objectives (Immunogenicity)	Immunogenicity rates after three doses of the ROTAVAC 5D in comparison to a placebo will be ascertained in approximately 150 subjects in each group assessed by fourfold rise in rotavirus-specific serum IgA antibody titers.	Day 28 (+) 5 days after the third dose in comparison to baseline levels